Controversies on chemotherapy for early HR+/HER2- breast cancer: The role of anthracyclines and dose intensification

Researchers conducted a patient-level meta-analysis to evaluate the efficacy of different adjuvant chemotherapy regimens and schedules in patients with HR+ HER2- breast cancer. They found a 14% lower recurrence rate among patients who received anthracycline in addition to a taxane-based chemotherapy regimen. They also found that adjuvant dose-dense chemotherapy is associated with a significant reduction in breast cancer recurrences and breast cancer mortality.